Any feedback?
Literature summary for 3.4.21.27 extracted from
- The use of desmopressin in congenital factor XI deficiency: a systematic review (2009), Ann. Hematol., 88, 931-935.
Activating Compound
| Activating Compound | Comment | Organism | Structure |
|---|---|---|---|
| desmopressin | increase of both FXI activity (up to 31%) and antigen levels 60 min after infusion. Also contradictory results with a lack of rise of FXI levels after infusion | Homo sapiens |  |
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | treatment options for FXI-deficient patients include virus-inactivated fresh frozen plasma, plasma-derived FXI concentrates, and activated recombinant FVII. Potential role of desmopressin for either treatment of bleeding episodes or the prevention of postoperative bleeding in patients with milder FXI defects. A single desmopressin infusion is sufficient to provide an efficient perioperative hemostasis | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | P03951 | - |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| factor XI | - |
Homo sapiens |
| FXI | - |
Homo sapiens |
General Information
| General Information | Comment | Organism |
|---|---|---|
| malfunction | FXI deficiency is a rare inherited coagulation disorder characterized by infrequent spontaneous bleeding, but increased risk of hemorrhagic complications especially after trauma or surgery | Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
